XORTX Therapeutics Inc. announced submission of a new patent for the treatment of chronic kidney disease (?CKD?). This patent is designed to protect new discoveries and strategies for the treatment of individuals with varied degrees of kidney function in the setting of CKD. Importantly, this patent entitled ?Oral and Sublingual Formulations of Xanthine Oxidase Inhibitors and Methods of Treating Disease?

outlines new formulations and methods for safer and more effective the use of xanthine oxidase inhibitors (XOI) in the setting of CKD in particular autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy (DN), IgA nephropathy, lupus nephritis and focal segmental glomerulosclerosis. The positive topline results from the XRX-OXY-101 bridging pharmacokinetic clinical study reported in First Quarter 2023 (the ?Study?) characterized the pharmacokinetics of the Company?s proprietary formulation of oral oxypurinol, XORLO?. Results from the Study showed that XORLO?

was well tolerated by the 88 subjects who received the drug. There were no safety concerns during the testing of drug across the various dosing regimens used. Overall results were positive and showed: i) a substantial increase in the bioavailability of oxypurinol with the XORLO?

formulation platform; (ii) a substantially increased dose proportionality compared to non-formulated oxypurinol; (iii) a multiple dosing regimen that achieved therapeutic target values. In simple terms, substantially increased early oral absorption of XORLO?, and increased circulating concentrations of oxypurinol necessary to inhibit production of uric acid across the desired therapeutic range and thereby slow down the advancements of CKD. Each of these results will provide key data to facilitate precise dosing recommendations for upcoming registration trials in individuals with progressing kidney disease due to ADPKD as well as other causes of CKD.